CD19 and viral infectious disease: We found that the factors that influenced the viral infection incidence after CD19 CAR-T therapy in both patient cohorts were similar, in particular, treatment lines, proportion of lymphocytes before CAR-T infusion, accepting HSCT before CAR-T therapy, and accepting G-CSF early after CAR-T therapy demonstrated statistical value.